Key points are not available for this paper at this time.
The ADC brentuximab vedotin was associated with manageable toxicity and induced objective responses in 75% of patients with relapsed or refractory HL after auto-SCT. Durable CRs approaching 2 years were observed, supporting study in earlier lines of therapy.
Building similarity graph...
Analyzing shared references across papers
Loading...
Anas Younes
Université Claude Bernard Lyon 1
Ajay K. Gopal
Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa
Scott E. Smith
The University of Texas Southwestern Medical Center
Journal of Clinical Oncology
The University of Texas MD Anderson Cancer Center
Building similarity graph...
Analyzing shared references across papers
Loading...
Younes et al. (Tue,) studied this question.
synapsesocial.com/papers/69d8240805ee2ba81dbef274 — DOI: https://doi.org/10.1200/jco.2011.38.0410